BOARD OF DIRECTORS

Mr. Kraus joined the company in August 2003 as Chief Executive Officer and Director. Mr. Kraus stepped down as CEO at the end of 2008 and was elected Chairman of the Board of Directors in January 2009. He brings along more than 25 years leadership experience in the dialysis and medical device industries. Prior to this, Mr. Kraus was President and CEO of medical startup NOvoVascular Inc. At NOvoVascular, he played a leadership role in the development of drug-coated stents for the treatment of cardiovascular disease, and facilitated the licensing of the company’s core intellectual property. Prior to NOvoVascular, Mr. Kraus was President and CEO of Althin Healthcare and Althin Medical, manufacturers of a complete line of hemodialysis products with revenues exceeding $100 million. In 1995 Althin Medical became a public company, and later was sold to Baxter International for $130 million. Mr. Kraus had previously been U.S. Manager and COO of Gambro, Inc., a leading medical technology and healthcare company that makes dialysis products, operates dialysis clinics and supplies blood bank technology worldwide. He directed the Initial Public Offering of Gambro in the United States in 1983 and grew sales volume four-fold. Gambro is now the second largest vertically integrated supplier of dialysis products and services worldwide, with revenues exceeding $2.7 billion.
Mr. Kraus earned a B.S. in Business Administration from St. Joseph ‘s University and has participated in the Executive Management Program at Harvard Business School . He is a member on the Board of Directors of the Medical Education Institute and MedaSorb Technologies Corporation and is a former Director of Victor Technologies, NOvoVascular, Althin BioPharm and Gambro.

Michael Bator was most recently a Managing Director of Healthcare Research at Jennison Associates, a U.S. mutual and pension fund management company that currently manages $188 billion in assets. During his 14 years at Jennison, Mr. Bator evaluated and recommended a wide array of investments in medical devices, European pharmaceuticals, managed care companies, and many others including well-known companies such as Medtronic, Abbott, Baxter, Johnson and Johnson, Novartis, AstraZeneca, Roche and GSK. Mr. Bator also has extensive management consulting experience, having spent many years with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University.

Dr. Phillip Chan is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the top performing and largest early stage investors in the greater New York region. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ advanced lipoplasty system in the U.S. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University. In 2012, Dr. Chan was named an Ernst & Young New Jersey Entrepreneur-of-the-Year finalist.

Edward Jones, MD, MBA is an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital. Dr. Jones is a practicing nephrologist as well as medical director of a dialysis facility for Fresenius Medical Care. He teaches renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine. Dr. Jones is a highly respected member of the renal research community.
He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He is a sixteen-year member of the Renal Physicians Association, the Philadelphia County Medical Society and a past president of the National Kidney Foundation of the Delaware Valley. Dr. Jones has been elected as the President of the Renal Physicians Association starting in 2009.

Ms. Kim is currently a Vice President at Zimmer Biomet, where she serves as the general manager of the Smart Implants portfolio and is responsible for leading the end-to-end program and product management for Zimmer Biomet’s Smart Implants technology in the orthopedic field. Previously, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Depression at LivaNova from 2020 to 2021. Prior to LivaNova, from 2011 to 2020, Ms. Kim served in increasing roles of responsibility at Johnson & Johnson Medical Devices. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences.

Alan D. Sobel is the Managing Member of Sobel & Co., LLC, a Livingston, NJ based full-service accounting, auditing, taxation, and business consulting firm with a diverse clientele including small and mid-sized businesses, non-profit agencies, SEC-registered companies, and individuals. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, amongst others. Alan is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. He earned a Bachelor of Science degree in Accountancy from Bentley College, and a Master of Science in Taxation from Fairleigh Dickinson University.

Mr. Rubin was a founder, Board Director, trusted advisor, and friend of CytoSorbents. Though his untimely passing in 2014 deeply saddened us, his countless contributions to this Company will not be forgotten.
For more about Mr. Rubin and his contributions, please see: Joseph Rubin – In Memoriam.